← Back to Search

MAPK Pathway Inhibitor

JSI-1187 for Solid Tumors

Phase 1
Waitlist Available
Research Sponsored by JS InnoPharm, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 35 months
Awards & highlights

Summary

This trial is testing a new drug, JSI-1187, as a possible treatment for cancer. It will be tested alone and in combination with another drug, dabrafenib. The study is for people with advanced solid tumors that have mutations in the MAPK pathway, which causes the pathway to be overactive.

Eligible Conditions
  • Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~35 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 35 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of treatment emergent adverse events (safety and tolerability)
Secondary outcome measures
Disease Control Rate
Duration of Response
Objective Response Rate
+3 more
Other outcome measures
Neoplasms
Mean plasma concentrations of JSI-1187 alone and in combination with dabrafenib
pRSK/RSK ratio in whole blood (PBMCs) (pharmacodynamic endpoint)

Side effects data

From 2016 Phase 3 trial • 251 Patients • NCT01227889
40%
Arthralgia
38%
Hyperkeratosis
36%
Headache
33%
Pyrexia
29%
Nausea
29%
Alopecia
26%
Fatigue
26%
Skin papilloma
22%
Back pain
22%
Vomiting
20%
Asthenia
20%
Palmar-plantar erythrodysaesthesia syndrome
19%
Rash
19%
Nasopharyngitis
18%
Cough
17%
Diarrhoea
17%
Myalgia
17%
Pain in extremity
15%
Dry skin
14%
Constipation
14%
Decreased appetite
12%
Chills
12%
Seborrhoeic keratosis
12%
Dyspnoea
12%
Actinic keratosis
10%
Musculoskeletal pain
10%
Erythema
9%
Insomnia
9%
Palmoplantar keratoderma
8%
Abdominal pain
8%
Dizziness
8%
Papilloma
7%
Influenza like illness
7%
Weight decreased
7%
Hyperglycaemia
7%
Hair texture abnormal
7%
Skin lesion
6%
Hypophosphataemia
6%
Pruritus
6%
Abdominal pain upper
6%
Folliculitis
6%
Upper respiratory tract infection
6%
Alanine aminotransferase increased
6%
Paraesthesia
6%
Acrochordon
6%
Melanocytic naevus
5%
Hypertension
5%
Aspartate aminotransferase increased
5%
Musculoskeletal chest pain
5%
Anxiety
5%
Eczema
5%
Oropharyngeal pain
5%
Anaemia
4%
Squamous cell carcinoma
4%
Squamous cell carcinoma of skin
3%
Basal cell carcinoma
2%
Ejection fraction decreased
2%
Malignant melanoma
2%
Malignant melanoma in situ
2%
Atrial fibrillation
1%
Anal abscess
1%
Pancreatitis acute
1%
Focal nodular hyperplasia
1%
Ileus
1%
Blood creatinine increased
1%
Cellulitis
1%
Papillary thyroid cancer
1%
Blood creatine phosphokinase increased
1%
Erysipelas
1%
Lip squamous cell carcinoma
1%
Breast cancer
1%
Cataract
1%
Febrile neutropenia
1%
Lymphadenopathy
1%
Acute coronary syndrome
1%
Cardiac failure congestive
1%
Myocardial infarction
1%
Myocardial ischaemia
1%
Colitis
1%
Haemorrhoidal haemorrhage
1%
Large intestine perforation
1%
Pancreatic necrosis
1%
Small intestinal perforation
1%
Euthanasia
1%
Abdominal infection
1%
Localised infection
1%
Perineal abscess
1%
Pleural infection
1%
Pneumonia
1%
Head injury
1%
Radius fracture
1%
Blood bilirubin increased
1%
Dehydration
1%
Diabetes mellitus
1%
Diabetes mellitus inadequate control
1%
Hyperlipasaemia
1%
Hyponatraemia
1%
Osteoporotic fracture
1%
Parkinsonism
1%
Presyncope
1%
Syncope
1%
Psychotic disorder
1%
Renal failure
1%
Urinary bladder polyp
1%
Hypoxia
1%
Pleural effusion
1%
Pulmonary embolism
1%
Pulmonary oedema
1%
Respiratory distress
1%
Dermal cyst
1%
Hypotension
1%
Acute myocardial infarction
1%
Pancreatitis
1%
Gait disturbance
1%
Pleuritic pain
1%
Hepatitis E
1%
Hepatic pain
1%
Joint effusion
1%
Muscular weakness
1%
Acoustic neuroma
1%
Adenocarcinoma of the cervix
1%
Transient ischaemic attack
1%
Haematoma
1%
Haemorrhage
1%
Bowen's disease
1%
Soft tissue sarcoma
100%
80%
60%
40%
20%
0%
Study treatment Arm
GSK2118436 150 mg BID
DTIC 1000 mg/m^2 in RP
GSK25118436 in the Crossover Phase

Trial Design

3Treatment groups
Experimental Treatment
Group I: Part C: JSI-1187 Plus Dabrafenib ExpansionExperimental Treatment2 Interventions
Cohort 1: BRAF V600E/K-mutated unresectable or metastatic melanoma after 1-3 prior therapies for metastatic disease, including anti-PD1 therapy, with or without ipilimumab, and BRAF/MEK inhibitor treatment. Cohort 2: BRAF V600E/K-mutated unresectable or metastatic melanoma after BRAF/MEK inhibitor adjuvant therapy for Stage 3 disease followed by 1-2 prior therapies for metastatic disease, including anti-PD-1 therapy, with or without ipilimumab, and excluding BRAF/MEK inhibitor treatment. Cohort 3: BRAF V600E-mutated metastatic NSCLC after 1-2 prior therapies for metastatic disease.
Group II: Part B: JSI-1187 Plus Dabrafenib Combination Dose EscalationExperimental Treatment2 Interventions
BRAF V600E/K-mutated unresectable or metastatic melanoma, BRAF V600E-mutated NSCLC, or BRAF V600E-mutated locally advanced or metastatic anaplastic thyroid cancer, or other BRAF V600E-mutated unresectable or metastatic solid tumors
Group III: Part A: JSI-1187 Monotherapy Dose EscalationExperimental Treatment1 Intervention
Locally advanced or metastatic solid tumors with confirmed with MAPK pathway mutation
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dabrafenib
2011
Completed Phase 3
~4120

Find a Location

Who is running the clinical trial?

JS InnoPharm, LLCLead Sponsor
1 Previous Clinical Trials
60 Total Patients Enrolled

Media Library

JSI-1187 (MAPK Pathway Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04418167 — Phase 1
Solid Tumors Research Study Groups: Part C: JSI-1187 Plus Dabrafenib Expansion, Part B: JSI-1187 Plus Dabrafenib Combination Dose Escalation, Part A: JSI-1187 Monotherapy Dose Escalation
Solid Tumors Clinical Trial 2023: JSI-1187 Highlights & Side Effects. Trial Name: NCT04418167 — Phase 1
JSI-1187 (MAPK Pathway Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04418167 — Phase 1
~14 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top